{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:14:51Z","timestamp":1786994091647,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medj.2025.100921","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:43:46Z","timestamp":1765554226000},"page":"100921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ramping up the express stairs: Lisaftoclax in CLL"],"prefix":"10.1016","volume":"6","author":[{"given":"Nawar","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100921_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100885","article-title":"Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b\/2 study","volume":"6","author":"Davids","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.medj.2025.100921_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.medj.2025.100921_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100921_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2025.100921_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100921_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100921_bib7","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100921_bib8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100921_bib9","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100921_bib10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/cancers16050980","article-title":"Venetoclax initiation in chronic lymphocytic leukemia: International insights and innovative approaches for optimal patient care","volume":"16","author":"Anderson","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:19:14Z","timestamp":1765556354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666634025003484"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100921","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ramping up the express stairs: Lisaftoclax in CLL","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100885","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100921"}}